Drugs / Sulforaphane
Sulforaphane
also known as
SFN · Avmacol Extra Strength · ZHIYINGUOSU · (r)-sulforaphane · 1-isothiocyanato-4R- (methylsulfinyl)butane · 4-(methylsulfinyl)butyl isothiocyanate · Isothiocyanate sulforaphane · SFX-01 · +2 more
Small molecule targets NFE2L2 via activation
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01568996 | Aug 2012 → Mar 2016 | melanocytic skin neoplasm, melanoma | John Kirkwood | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05153174 | May 2022 → May 2023 | chronic kidney disease | University of Rochester | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00946309 | Jul 2010 → May 2014 | prostate cancer | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 213 trials · 2 met primary | ||||||
| Phase 2 | NCT07040280 | Feb 2026 → Mar 2031 expected | cutaneous melanoma, melanocytic nevus | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05797506 | May 2023 → Apr 2025 | chronic kidney disease | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT05084365 | Nov 2021 → Nov 2023 | Parkinson disease | Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT04521868 | Aug 2020 → Aug 2022 | schizophrenia | Central South University | Completed | Met primary |
| Phase 2 | NCT04252261 | Jun 2020 → Dec 2021 | — | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT03232138 | Jan 2018 → Feb 2023 | lung cancer | Jian-Min Yuan, MD | Completed | Mixed |
| Phase 2 | NCT03126539 | Sep 2017 → Jan 2019 | — | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT02810964 | Feb 2017 → Nov 2019 | schizoaffective disorder, schizophrenia | Sheppard Pratt Health System | Completed | No outcome recorded |
| Phase 2 | NCT02970682 | Oct 2016 → Jan 2019 | breast neoplasm | Evgen Pharma | Completed | Met primary |
| Phase 2 | NCT02677051 | Feb 2016 → Dec 2025 overdue | autism | Rutgers, The State University of New Jersey | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01474993 | Dec 2011 → Nov 2013 | autism | Andrew Zimmerman | Completed | No outcome recorded |
| Phase 2 | NCT01437501 | Oct 2011 → Jan 2012 | — | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 2 | NCT01228084 | Nov 2010 → May 2012 | prostate adenocarcinoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03932136 | Jul 2019 → Dec 2026 expected | psychotic disorder | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05224492 | Feb → Jul 2022 | HIV infectious disease | Sunshine Specialty Health Care | Unknown | No outcome recorded |
| Phase 4 | NCT05148169 | Jan 2020 → Dec 2022 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT05145270 | Nov 2019 → Nov 2022 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01265953 | Jul 2011 → Oct 2015 | prostate cancer | Portland VA Medical Center | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 0 | NCT03730649 Comparator | Oct 2019 → Mar 2025 overdue | skin atrophy | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05408559 Comparator | Jul 2022 → Sep 2025 | diastolic heart failure, systolic heart failure | Texas Tech University Health Sciences Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03934905 Comparator | Jun 2022 → Nov 2028 expected | cardiomyopathy due to anthracyclines | Texas Tech University Health Sciences Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02561481 Comparator | Dec 2015 → Dec 2018 | autism spectrum disorder | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT05653492 Comparator | May 2023 → Apr 2025 overdue | kidney disorder | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04246905 Comparator | Jul 2020 → Dec 2021 | depressive disorder | Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT03517995 Comparator | Apr 2020 → Dec 2021 | urinary bladder cancer, urothelial carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02909959 Comparator | Mar 2017 → May 2019 | autism | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02614742 Comparator | Apr 2016 → Sep 2019 | acquired aneurysmal subarachnoid hemorrhage | Evgen Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02801448 Comparator | Sep 2015 → Jun 2020 | type 2 diabetes mellitus | Anders Rosengren, MD PhD | Completed | No outcome recorded |
| Phase 2 | NCT01845220 Comparator | Apr 2014 → Jul 2015 | alcohol sensitivity, acute | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01335971 Comparator | Sep 2010 → Jul 2013 | chronic obstructive pulmonary disease | Johns Hopkins University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-11-10 | Evgen Pharma | Results Publication of data on SFX-01 in glioblastoma investis.com ↗
The in vitro data, in GBM cells and patient-derived glioma-initiating cells, show anti-tumour activity of the Company's lead asset SFX-01. |
| 2021-09-20 | Evgen Pharma | Results Publication of data in glioblastoma cells investis.com ↗
The in vitro data show effectiveness of the Company's lead asset SFX-01 in glioblastoma cells and 3D spheroids from several patients in New Zealand , together with the more commonly used commercially available cell lines. |
| 2019-11-11 | Evgen Pharma | Results SFX-01 results in SAS study investis.com ↗
The primary endpoint of reducing blood flow velocity in the middle cerebral artery was not achieved, with no significant difference between the SFX-01 and placebo arms. |
| 2019-09-30 | Evgen Pharma | Results ESMO presentation of Phase II STEM clinical data investis.com ↗
The trial data also showed that SFX-01, in combination with endocrine therapy , demonstrated both anti-tumour activity and prolonged disease stabilisation in heavily pre-treated patients progressing on endocrine therapy at entry to the study. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-10 | Evgen Pharma | Publication of data on SFX-01 in glioblastoma investis.com ↗ |
| 2021-09-20 | Evgen Pharma | Publication of data in glioblastoma cells investis.com ↗ |
| 2019-11-11 | Evgen Pharma | SFX-01 results in SAS study investis.com ↗ |
| 2019-09-30 | Evgen Pharma | ESMO presentation of Phase II STEM clinical data investis.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulforaphane | “A 12-week, randomized controlled trial (RCT) will be conducted to explore the effect of add-on sulforaphane (SFN) to selective serotonin reuptake inhibitors (SSRIs) for major...” NCT05148169 ↗31“Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates);...” NCT05145270 ↗ “Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.” NCT03932136 ↗ “Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.” NCT01437501 ↗ “Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.” PMID 31155953 ↗ Jun 2019 “150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge” NCT01845220 ↗ “Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.” NCT03232138 ↗ “SFX-01 is a novel drug for clinical delivery of sulforaphane (SFN).” PMID 39028412 ↗ Jul 2024 |
| Known as | (r)-sulforaphane | ChEMBL registry synonym — accepted as the source's own label CHEMBL48802 ↗ |
| Known as | 1-isothiocyanato-4R- (methylsulfinyl)butane | “Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate that is delivered by lyophilized extracts of 3-day-old broccoli sprouts.” NCT01474993 ↗ |
| Known as | 4-(methylsulfinyl)butyl isothiocyanate | ChEMBL registry synonym — accepted as the source's own label CHEMBL48802 ↗ |
| Known as | Avmacol Extra Strength | “Participants were randomly assigned (2:1) to receive antipsychotics plus sulforaphane (1,700 mg Avmacol Extra Strength sulforaphane daily) or antipsychotics plus placebo for 24 weeks.” PMID 39832347 ↗ Jan 20251“Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease” NCT05797506 ↗ |
| Known as | Isothiocyanate sulforaphane | “Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.” NCT03126539 ↗ |
| Known as | SFN | “One hundred and eighty adults diagnosed with major depressive disorder (MDD) with no or poor response to initial antidepressant treatment will be recruited. Then all the...” NCT05145270 ↗2“A 12-week, randomized controlled trial (RCT) will be conducted to explore the effect of add-on sulforaphane (SFN) to selective serotonin reuptake inhibitors (SSRIs) for major...” NCT05148169 ↗ “the phytochemical sulforaphane (SFN)” NCT03934905 ↗ |
| Known as | SFX-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02970682 ↗ |
| Known as | Sulforaphane Nutraceutical | “Sulforaphane Nutraceutical 6 tablets by mouth daily” NCT02810964 ↗ |
| Known as | Sulforaphane, (r)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL48802 ↗ |
| Known as | ZHIYINGUOSU | “Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates);...” NCT05145270 ↗1“The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight.” NCT05148169 ↗ |
| Action | Inhibit | “will inhibit growth of prostate cancer cells.” NCT00946309 ↗ |
| Modality | Small molecule | “SFN, an isothiocyanate found in cruciferous vegetables” NCT01265953 ↗ |
| Route | Oral | “Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7.” NCT01228084 ↗ |
| Target | NFE2L2 | “This trial focuses on sulforaphane, a derivative of cruciferous vegetables, which is a potent stimulator of Nrf2 activity.” NCT01335971 ↗ |